LOGIN
CART
MY ACCOUNT
North America
Australia
Austria
Belgium
China
Denmark
Finland
France
Germany
Hong Kong
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Korea
Luxembourg
Malaysia
Netherlands
Norway
Singapore
Spain
Sweden
Switzerland
Taiwan
Thailand
United Kingdom
Vietnam
Gene Search
Antigen Profiler
BLAST
Enter search terms and hit enter or click the submit button.
Single letter AA sequence:
Score:
Advanced Peptide Design
Nucleotide
Peptide
(enter accession number or fasta sequence)
Database:
(choose database)
ALL Mammalian
ALL Non-mammalian
Homo sapiens
Mus Musculus
Rat
Canine
Primate
Bos Taurus
Danio rerio
Drosophila (All) (rel.1)
Fugu rubripes (All) (rel.1)
Macaca mulatta (All) (rel.1)
C. jejuni (All) (rel.1)
Xenopus laevis
Xenopus tropicalis
Incyte (All Species)
Submitted
0
Complete
0
Advanced (more options)
Products
Promotions
Programs
Distributors
Support
Who We Are
Contact Us
Open Biosystems Launches Inducible Lentiviral shRNAmir Library for RNAi
First commercial offering for inducible RNAi triggers targeting the human genome
HUNTSVILLE, Ala.—August 1, 2007—
Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery and validation, today announced the release of the newest generation of shRNAmir libraries with its Expression Arrest™ TRIPZ™ inducible lentiviral shRNAmir library for RNAi. Targeting the entire human genome with multiple shRNAmir constructs per gene, the TRIPZ inducible lentiviral shRNAmir library builds on Open Biosystems' proven vector-based RNAi technologies that enable researchers to quickly realize the inherent value of vector-based RNAi. This offering for inducible RNAi, the first of its kind, allows for rapid validation of drug targets by the creation of in vivo animal models, a necessary step in the drug discovery process.
The TRIPZ library consists of shRNAmir constructs that have been pre-cloned into a Tetracycline-inducible lentiviral vector, resulting in a powerful RNAi trigger that expands the potential of RNAi to cell and animal models previously refractory to RNAi. Open Biosystems' TRIPZ shRNAmir provides researchers and scientists with options for tightly regulated RNAi and increased delivery range into a vast number of cell types from primary and non-dividing cells to in vivo animal models.
"Inducible Lentiviral shRNAmir takes RNAi research to the next level. The new TRIPZ™ inducible shRNAmir makes it possible to both analyze the effect of gene knockdown as well as validate that result in the same experiment. Open Biosystems continues to arm the research community with leading edge technologies necessary to propel and sustain biological research," said Gwen Fewell, PhD. Product Manager for RNAi at Open Biosystems.
Expression Arrest human TRIPZ lentiviral shRNAmir is available immediately as individual shRNAmir constructs, target gene sets or a whole genome library subscription. For additional information about the human TRIPZ inducible lentiviral shRNAmir library, please contact
info@openbiosystems.com
.
About Open Biosystems
Open Biosystems, Inc. develops manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit: www.openbiosystems.com.
Contacts:
Gwen D. Fewell, PhD
Open Biosystems Inc.
gfewell@openbiosystems.com
1-888-412-2225
|
My Account
|
Privacy Policy
|
Terms & Conditions
© 2005-2007 Open Biosystems All Rights Reserved